Specifically, the company plans to present: Additional data from IMM-1-104 in combination with mGnP in first-line pancreatic cancer. Initial data from IMM-1-104 in combination with mFFX in first ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...

Immuneering will retain global development and commercialization rights to IMM-1-104, an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and address RAS-driven tumors.

In December 2024, the FDA awarded fast-track designation to IMM-1-104 for treating patients with unresectable or metastatic NRAS-mutant melanoma who have either progressed on or cannot tolerate PD ...

American biotechs Immuneering and Regeneron, both focused on cancer research, have come together to develop IMM-1-104, a small molecule cyclic inhibitor, in the clinic. The drug owned by Immuneering ...

White Gold announces results of 2024 exploration diamond drilling programs at the QV and Betty properties. The initial diamond drilling program at the Chris Creek target encountered a broad near ...

Meetings to be held March 10-11 hosted by Oppenheimer. Discover the Best Stocks and Maximize Your Portfolio: See what stocks are receiving ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...